日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies

吡咯替尼或吡咯替尼联合卡培他滨治疗HER2阳性转移性乳腺癌患者的生存获益和生物标志物分析：两项I期研究的汇总分析

期刊:Biomarker Research
影响因子:11.5
doi:10.1186/s40364-023-00453-0
Guan, Xiuwen; Ma, Fei; Li, Qiao; Chen, Shanshan; Lan, Bo; Fan, Ying; Wang, Jiayu; Luo, Yang; Cai, Ruigang; Zhang, Pin; Li, Qing; Xu, Binghe
肿瘤免疫
HER2
肿瘤
乳腺癌
发表日期：2023
文献解析 文献求助 收藏

A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer

一项针对中国晚期乳腺癌患者的 1 期临床研究，评估了细胞周期蛋白依赖性激酶 4/6 抑制剂 dalpiciclib 的疗效

期刊:Biomarker Research
影响因子:11.5
doi:10.1186/s40364-021-00271-2
Zhang, Pin; Xu, Binghe; Gui, Lin; Wang, Wenna; Xiu, Meng; Zhang, Xiao; Sun, Guilan; Zhu, Xiaoyu; Zou, Jianjun
信号转导
乳腺癌
肿瘤
细胞生物学
肿瘤免疫
发表日期：2021
文献解析 文献求助 收藏

Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer

m6A RNA甲基化修饰在乳腺癌中的表达及其临床预后价值

期刊:Biomarker Research
影响因子:11.5
doi:10.1186/s40364-021-00285-w
Zheng, Fangchao; Du, Feng; Qian, Haili; Zhao, Jiuda; Wang, Xue; Yue, Jian; Hu, Nanlin; Si, Yiran; Xu, Binghe; Yuan, Peng
m6A/m5C/m7G
肿瘤
表观遗传
肿瘤免疫
乳腺癌
发表日期：2021
文献解析 文献求助 收藏

The emerging role of RNA N6-methyladenosine methylation in breast cancer

RNA N6-甲基腺苷甲基化在乳腺癌中的新兴作用

期刊:Biomarker Research
影响因子:11.5
doi:10.1186/s40364-021-00295-8
Zheng, Fangchao; Du, Feng; Zhao, Jiuda; Wang, Xue; Si, Yiran; Jin, Peng; Qian, Haili; Xu, Binghe; Yuan, Peng
肿瘤
表观遗传
乳腺癌
肿瘤免疫
发表日期：2021
文献解析 文献求助 收藏

Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial

吡咯替尼或安慰剂联合曲妥珠单抗和多西他赛治疗HER2阳性转移性乳腺癌：随机3期PHILA试验的长期生存结果

期刊:Bmj-British Medical Journal
影响因子:42.7
doi:10.1136/bmj-2025-087259
Ma, Fei; Yan, Min; Li, Wei; Ouyang, Quchang; Tong, Zhongsheng; Teng, Yuee; Wang, Yongsheng; Wang, Shusen; Geng, Cuizhi; Luo, Ting; Zhong, Jincai; Zhang, Qingyuan; Liu, Qiang; Zeng, Xiaohua; Sun, Tao; Mo, Qinguo; Zhou, Shoubing; Li, Peidong; Cheng, Jing; Wang, Xiaojia; Nie, Jianyun; Yang, Jin; Wu, Xinhong; Wang, Xinshuai; Li, Huiping; Yao, Guangyu; Fan, Yang; Lin, Jiaman; Zhu, Xiaoyu; Xu, Binghe
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial

比瑞西尼联合氟维司群治疗内分泌进展后的晚期乳腺癌：BRIGHT-2 III期随机临床试验

期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2026.0318
Wang, Jiayu; Zhang, Qingyuan; Li, Huiping; Tong, Zhongsheng; Ouyang, Quchang; Li, Huihui; Teng, Yuee; Wang, Biyun; Sun, Tao; Wang, Jingfen; Li, Wei; Niu, Zhaofeng; Li, Hongsheng; Gong, Chang; Wang, Shu; Wang, Xinshuai; Wu, Xinhong; Liu, Ning; Yu, Guohua; Hu, Yan; Wang, Qiuli; Duan, Xianghui; Yang, Fan; Wang, Li; Xu, Binghe
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial

阿福塞替尼联合氟维司群治疗既往接受过治疗的HR阳性、HER2阴性晚期乳腺癌：一项Ib期试验

期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-026-69225-2
Zhang, Pin; Sun, Tao; Wang, Ying; Li, Wei; Tong, Zhongsheng; Phadke, Sneha; Feinstein, Trevor; Ma, Wenyue; Guo, Pengfei; Zhang, Minhua; Yue, Yong; Xu, Binghe
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Red Blood Cells Internalize Extracellular DNA via Apoptotic Bodies with Clinical Relevance to Cancer Patients

红细胞通过凋亡小体内化细胞外DNA，这对癌症患者具有临床意义

期刊:Advanced Science
影响因子:14.1
doi:10.1002/advs.202511408
Zeng, Zihang; Yi, Zongbi; Hu, Jing; Li, Jiali; Xu, Yu; Guo, Xiuli; Ji, Qian; Feng, Kaixiang; Zhang, Ying; Bai, Sirui; Tan, Yushuang; Yan, Yufei; Han, Linzhi; Jiang, Jing; Wang, Tengfei; Wang, Xiang; Zhan, Ziqing; Huang, Ruiying; Zhang, Jinfang; Xie, Conghua; Xu, Binghe
肿瘤
凋亡
表观遗传
肿瘤免疫
红细胞
细胞生物学
发表日期：2026
文献求助 收藏

Extracellular matrix-derived mechanical force induces CDK4/6 inhibitor resistance by inhibiting NEK10 dependent cell cycle regulation in breast cancer

细胞外基质衍生的机械力通过抑制NEK10依赖的细胞周期调控，诱导乳腺癌细胞产生CDK4/6抑制剂耐药性。

期刊:International Journal of Surgery
影响因子:10.1
doi:10.1097/JS9.0000000000004527
Li, Cong; Wang, Jian; Jin, Yuming; Huang, Yumeng; Hong, Ruoxi; Chen, Dongshao; Lin, Shaoyan; Chen, Limin; Wu, Huailiang; Du, Ting; Xu, Binghe; Wang, Wan; Wang, Shusen
CDK4
肿瘤
肿瘤免疫
信号转导
乳腺癌
NEK1
细胞生物学
发表日期：2026
文献求助 收藏

Association between diarrhea and survival in patients with HER2-positive advanced breast cancer treated with pyrotinib-based therapy: A landmark analysis from the real-world PRETTY study

腹泻与接受吡咯替尼治疗的 HER2 阳性晚期乳腺癌患者生存率之间的关联：来自真实世界 PRETTY 研究的里程碑式分析

期刊:Breast
影响因子:7.9
doi:10.1016/j.breast.2026.104783
Li, Yiqun; Wang, Wenna; Tong, Zhongsheng; Wu, Xinhong; Cai, Li; Ouyang, Quchang; Li, Wei; Yu, Zhiyong; Han, Zhengxiang; Wang, Xiaojia; Li, Man; Wang, Haibo; Li, Li; Yang, Jin; Xu, Binghe
肿瘤
RET
HER2
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏